Showing results (21-30 of 28) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Cell Chemical Biology|January 3, 2026
Identification of aryl hydrocarbon receptor as a functional target that enhances astrocytic ApoE secretionKirk W Donovan, Eric Stefan, Bekim Bajrami, et al.ACS Chemical Neuroscience|February 22, 2023
Elucidation of the GSK3α Structure Informs the Design of Novel, Paralog-Selective InhibitorsBrenda Amaral, Andrew Capacci, Trip Anderson, et al.Journal of Medicinal Chemistry|July 23, 2020
Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune DiseasesBin Ma, Tonika Bohnert, Kevin L Otipoby, et al.Science Signaling|August 2, 2018
CDK12-mediated transcriptional regulation of noncanonical NF-κB components is essential for signalingKate L Henry, Debra Kellner, Bekim Bajrami, et al.Journal of Medicinal Chemistry|April 7, 2026
Leveraging Kinase Drugs for Neurosciences: Discovery of Selective, CNS-Penetrant Reversible Bruton's Tyrosine Kinase Inhibitors as Therapeutics for NeuroinflammationBrian T Hopkins, Isaac E Marx, Harlod George Vandeveer, et al.Clinical & Translational Immunology|June 18, 2021
Next-generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cellsEris Bame, Hao Tang, Jeremy C Burns, et al.Journal of Medicinal Chemistry|November 4, 2021
Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple SclerosisBrian T Hopkins, Eris Bame, Bekim Bajrami, et al.Journal of Medicinal Chemistry|May 7, 2024
Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple SclerosisMartin K Himmelbauer, Bekim Bajrami, Rebecca Basile, et al.Pageof 3